Results 141 to 150 of about 5,469,182 (343)

Transitioning of protein substitutes in patients with phenylketonuria: a pilot study

Frontiers in Nutrition
IntroductionIn phenylketonuria (PKU), there is limited information about transitioning between protein substitutes and the influencing factors, particularly in young children.
Ozlem Yilmaz Nas, Ozlem Yilmaz Nas, Ozlem Yilmaz Nas, Catherine Ashmore, Sharon Evans, Alex Pinto, Anne Daly, Nurcan Yabanci Ayhan, Anita MacDonald   +8 more
doaj   +1 more source

Combinations of Peanut Meal and Blood Meal as Substitutes for Soybean Meal in Corn-Based, Growing-Finishing Pig Diets [PDF]

, 1984
J. O. Ilori, E. R. Miller, D. E. Ullrey, P. K. Ku, M. G. Hogberg   +4 more
openalex   +1 more source

Surgeon Speaks-Paul J. DiMuzio, MD, FACS [PDF]

, 2014
“Patients with extensive acute deep vein thrombosis (DVT) of the legs provide an excellent example of why effective medical-surgical collaboration is so important.

core   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Effects of salt substitute on urinary electrolytes and blood pressure in a real-world setting—cohort study in Hunan, China

Frontiers in Nutrition
Background and aimsSalt substitute is considered an effective strategy to reduce sodium and increase potassium intake and thereby lower blood pressure in China, but its benefits and risks are uncertain in real-world data.
Hao Wu, Wenbin Ouyang, Jing Deng, Yongmei He, Lu Yin, Xia Cao, Zhiheng Chen, Pingting Yang, Yaqin Wang, Ying Li, Xin Huang   +10 more
doaj   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Influence on Blood Pressure of Oestrogen Substitution Therapy in the Menopause [PDF]

, 1987
Robert Eggertsen
openalex   +1 more source

Preparation and exchange transfusion effect of a double polymerization human umbilical cord haemoglobin of red blood cell substitute

, 2023
Wentao Zhou, Shen Li, Shasha Hao, Xintong Xie, Honghui Zhang, Jiaxin Liu, Hong Wang, Yang Chengmin   +7 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source